Cabergoline Decreases Alcohol Drinking and Seeking Behaviors Via Glial Cell Line-Derived Neurotrophic Factor

Biological Psychiatry

Volumn 66, Issue 2, 2009, Pages 146-153

  Carnicella, Sebastien ^a   Ahmadiantehrani, Somayeh ^a   He, Dao Yao ^a   Nielsen, Carsten K ^a   Bartlett, Selena E ^a   Janak, Patricia H ^a   Ron, Dorit ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Addiction; alcohol; cabergoline; GDNF; growth factor; treatment

Indexed keywords

ALCOHOL; CABERGOLINE; DOPAMINE 2 RECEPTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); SULFUR 35;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BINDING ASSAY; CELL ACTIVATION; CELL LINE; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG SELF ADMINISTRATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HETEROZYGOTE; HUMAN; HUMAN CELL; INSTRUMENTAL CONDITIONING; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; REINFORCEMENT; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING; WITHDRAWAL SYNDROME;

ALCOHOL DETERRENTS; ALCOHOL DRINKING; ANIMALS; CONDITIONING, OPERANT; DOPAMINE AGONISTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERGOLINES; EXTINCTION, PSYCHOLOGICAL; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INJECTIONS, INTRAPERITONEAL; MESENCEPHALON; MICE; MICE, KNOCKOUT; MICROINJECTIONS; RATS; SELF ADMINISTRATION; SUBSTANTIA NIGRA;

EID: 67449092774     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.12.022     Document Type: Article

References (59)

1. World Health Organization. WHO global status report on alcohol 2004 (2004), World Health Organization, Geneva
2. Heilig M., and Egli M. Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms. Pharmacol Ther 111 (2006) 855-876
3. Assanangkornchai S., and Srisurapanont M. The treatment of alcohol dependence. Curr Opin Psychiatry 20 (2007) 222-227
4. Johnson B.A. Update on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings. Biochem Pharmacol 75 (2008) 34-56
5. Bouza C., Angeles M., Munoz A., and Amate J.M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 99 (2004) 811-828
6. Millan M.J., Maiofiss L., Cussac D., Audinot V., Boutin J.A., and Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303 (2002) 791-804
7. Newman-Tancredi A., Cussac D., Audinot V., Nicolas J.P., De Ceuninck F., Boutin J.A., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 303 (2002) 805-814
8. Newman-Tancredi A., Cussac D., Quentric Y., Touzard M., Verriele L., Carpentier N., et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 303 (2002) 815-822
9. Ohta K., Fujinami A., Kuno S., Sakakimoto A., Matsui H., Kawahara Y., et al. Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture. Pharmacology 71 (2004) 162-168
10. Ohta K., Kuno S., Mizuta I., Fujinami A., Matsui H., and Ohta M. Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes. Life Sci 73 (2003) 617-626
11. Airaksinen M.S., and Saarma M. The GDNF family: Signalling, biological functions and therapeutic value. Nat Rev Neurosci 3 (2002) 383-394
12. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
13. Pascual A., Hidalgo-Figueroa M., Piruat J.I., Pintado C.O., Gomez-Diaz R., and Lopez-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11 (2008) 755-761
14. Beck K.D., Valverde J., Alexi T., Poulsen K., Moffat B., Vandlen R.A., et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373 (1995) 339-341
15. Sarabi A., Hoffer B.J., Olson L., and Morales M. GFRalpha-1 mRNA in dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area. J Comp Neurol 441 (2001) 106-117
16. Trupp M., Belluardo N., Funakoshi H., and Ibanez C.F. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple mechanisms of trophic actions in the adult rat CNS. J Neurosci 17 (1997) 3554-3567
17. Koob G.F., Sanna P.P., and Bloom F.E. Neuroscience of addiction. Neuron 21 (1998) 467-476
18. McBride W.J., Murphy J.M., and Ikemoto S. Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies. Behav Brain Res 101 (1999) 129-152
19. He D.Y., McGough N.N., Ravindranathan A., Jeanblanc J., Logrip M.L., Phamluong K., et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci 25 (2005) 619-628
20. Carnicella S., Kharazia V., Jeanblanc J., Janak P.H., and Ron D. GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse. Proc Natl Acad Sci U S A 105 (2008) 8114-8119
21. Miyagi M., Arai N., Taya F., Itoh F., Komatsu Y., Kojima M., et al. Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents. Biol Pharm Bull 19 (1996) 1499-1502
22. Miyagi M., Itoh F., Taya F., Arai N., Isaji M., Kojima M., et al. Dopamine receptor affinities in vitro and stereotypic activities in vivo of cabergoline in rats. Biol Pharm Bull 19 (1996) 1210-1213
23. Carnicella S., Amamoto R., and Ron D. Excessive alcohol consumption is blocked by GDNF. Alcohol 43 (2009) 35-43
24. Wise R.A. Voluntary ethanol intake in rats following exposure to ethanol on various schedules. Psychopharmacologia 29 (1973) 203-210
25. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed. (1998), Academic Press, San Diego
26. Ikemoto S. Dopamine reward circuitry: Two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev 56 (2007) 27-78
27. Rodd Z.A., Melendez R.I., Bell R.L., Kuc K.A., Zhang Y., Murphy J.M., et al. Intracranial self-administration of ethanol within the ventral tegmental area of male Wistar rats: Evidence for involvement of dopamine neurons. J Neurosci 24 (2004) 1050-1057
28. Bouton M.E. Context, ambiguity, and unlearning: Sources of relapse after behavioral extinction. Biol Psychiatry 52 (2002) 976-986
29. Le A., and Shaham Y. Neurobiology of relapse to alcohol in rats. Pharmacol Ther 94 (2002) 137-156
30. Epstein D.H., Preston K.L., Stewart J., and Shaham Y. Toward a model of drug relapse: An assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl) 189 (2006) 1-16
31. Vengeliene V., Bilbao A., Molander A., and Spanagel R. Neuropharmacology of alcohol addiction. Br J Pharmacol 154 (2008) 299-315
32. Guo H., Tang Z., Yu Y., Xu L., Jin G., and Zhou J. Apomorphine induces trophic factors that support fetal rat mesencephalic dopaminergic neurons in cultures. Eur J Neurosci 16 (2002) 1861-1870
33. Du F., Li R., Huang Y., Li X., and Le W. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 22 (2005) 2422-2430
34. Steensland P., Simms J.A., Holgate J., Richards J.K., and Bartlett S.E. Varenicline, an {alpha}4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A 104 (2007) 12518-12523
35. Escher T., and Mittleman G. Schedule-induced alcohol drinking: Non-selective effects of acamprosate and naltrexone. Addict Biol 11 (2006) 55-63
36. Hollister L.E., Johnson K., Boukhabza D., and Gillespie H.K. Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend 8 (1981) 37-41
37. Crowley T.J., Wagner J.E., Zerbe G., and Macdonald M. Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry 142 (1985) 1081-1084
38. Wang J., Carnicella S., Phamluong K., Jeanblanc J., Ronesi J.A., Chaudhri N., et al. Ethanol induces long-term facilitation of NR2B-NMDA receptor activity in the dorsal striatum: Implications for alcohol drinking behavior. J Neurosci 27 (2007) 3593-3602
39. Vanderschuren L.J., Di Ciano P., and Everitt B.J. Involvement of the dorsal striatum in cue-controlled cocaine seeking. J Neurosci 25 (2005) 8665-8670
40. Jeanblanc J., He D.Y., McGough N.N., Logrip M.L., Phamluong K., Janak P.H., et al. The dopamine D3 receptor is part of a homeostatic pathway regulating ethanol consumption. J Neurosci 26 (2006) 1457-1464
41. Everitt B.J., and Robbins T.W. Neural systems of reinforcement for drug addiction: From actions to habits to compulsion. Nat Neurosci 8 (2005) 1481-1489
42. Volkow N.D., Wang G.J., Telang F., Fowler J.S., Logan J., Childress A.R., et al. Cocaine cues and dopamine in dorsal striatum: Mechanism of craving in cocaine addiction. J Neurosci 26 (2006) 6583-6588
43. Weinshenker D., and Schroeder J.P. There and back again: A tale of norepinephrine and drug addiction. Neuropsychopharmacology 32 (2007) 1433-1451
44. Airavaara M., Planken A., Gaddnas H., Piepponen T.P., Saarma M., and Ahtee L. Increased extracellular dopamine concentrations and FosB/DeltaFosB expression in striatal brain areas of heterozygous GDNF knockout mice. Eur J Neurosci 20 (2004) 2336-2344
45. Carnicella S., and Ron D. GDNF-A potential target to treat addiction [published online ahead of print December 24]. Pharmacol Ther (2008)
46. Hyman S.E., Malenka R.C., and Nestler E.J. Neural mechanisms of addiction: The role of reward-related learning and memory. Annu Rev Neurosci 29 (2006) 565-598
47. Ortiz J., Fitzgerald L.W., Charlton M., Lane S., Trevisan L., Guitart X., et al. Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system. Synapse 21 (1995) 289-298
48. Messer C.J., Eisch A.J., Carlezon Jr. W.A., Whisler K., Shen L., Wolf D.H., et al. Role for GDNF in biochemical and behavioral adaptations to drugs of abuse. Neuron 26 (2000) 247-257
49. Niwa M., Nitta A., Yamada Y., Nakajima A., Saito K., Seishima M., et al. An inducer for glial cell line-derived neurotrophic factor and tumor necrosis factor-alpha protects against methamphetamine-induced rewarding effects and sensitization. Biol Psychiatry 61 (2007) 890-901
50. Colao A., Di Sarno A., Guerra E., De Leo M., Mentone A., and Lombardi G. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat Clin Pract Endocrinol Metab 2 (2006) 200-210
51. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., and Scanlon M.F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331 (1994) 904-909
52. Jankovic J., and Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 21 (2007) 677-692
53. Bonuccelli U. Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurol 16 Suppl 1 (2003) S13-S19
54. Kars M., Pereira A.M., Bax J.J., and Romijn J.A. Cabergoline and cardiac valve disease in prolactinoma patients: Additional studies during long-term treatment are required. Eur J Endocrinol 159 (2008) 363-367
55. De Rosa M., Ciccarelli A., Zarrilli S., Guerra E., Gaccione M., Di Sarno A., et al. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol (Oxf) 64 (2006) 307-313
56. Colao A., Galderisi M., Di Sarno A., Pardo M., Gaccione M., D'Andrea M., et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93 (2008) 3777-3784
57. Bogazzi F., Buralli S., Manetti L., Raffaelli V., Cigni T., Lombardi M., et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract (2008)
58. Benedetti M.S., Dostert P., Barone D., Efthymiopoulos C., Peretti G., and Roncucci R. In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine. Eur J Pharmacol 187 (1990) 399-408
59. Shoptaw S., Watson D.W., Reiber C., Rawson R.A., Montgomery M.A., Majewska M.D., et al. Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). Addiction 100 suppl 1 (2005) 78-90